Samidorphan

CAT:
804-HY-123689-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Samidorphan - image 1

Samidorphan

  • Description :

    Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals[1][2][3][4][5].
  • Product Name Alternative :

    ALKS-33; RDC-0313
  • UNSPSC :

    12352005
  • Target :

    Opioid Receptor
  • Type :

    Reference compound
  • Related Pathways :

    GPCR/G Protein; Neuronal Signaling
  • Applications :

    Neuroscience-Neuromodulation
  • Field of Research :

    Neurological Disease
  • Assay Protocol :

    https://www.medchemexpress.com/samidorphan.html
  • Concentration :

    10mM
  • Purity :

    99.04
  • Solubility :

    DMSO : 200 mg/mL (ultrasonic)
  • Smiles :

    O=C(N)C1=CC=C(C[C@H]([C@@]2(CC3)O)N(CC4)CC5CC5)C([C@]42CC3=O)=C1O
  • Molecular Formula :

    C21H26N2O4
  • Molecular Weight :

    370.44
  • References & Citations :

    [1]McElroy SL, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46 (3) :239-45.|[2]Mark S. Todtenkopf, et al. Buprenorphine in Combination with Samidorphan (ALKS 33) Results in Antidepressive-Like Effects in Two Distinct Rat Models. Eur Neuropsychopharmacol. 2014;24aSuppl 2) :S366.|[3]Rehan ST, et al. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond) . 2022 Jun 30;79:104115.|[4]Shravni V, et al. Comparative Effects of Buprenorphine and Samidorphan on Locomotor Behavior in vivo. Scientific Research Journal of Pharmacy 2021, Volume 1, Issue: 1 (June-July) . |[5]Smith KL, et al. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat. Neuropharmacology. 2019 Mar 1;146:316-326.
  • Shipping Conditions :

    Blue Ice
  • Storage Conditions :

    -20°C, 3 years (Powder)
  • Scientific Category :

    Reference compound1
  • Clinical Information :

    Launched
  • CAS Number :

    [852626-89-2]

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide